Impact BioMedical
9 hedge funds and large institutions have $59.3K invested in Impact BioMedical in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.26% more ownership
Funds ownership: 0% → 0.26% (+0.26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$31.6K |
| 2 |
HF
HRT Financial
New York
|
+$29.6K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$6.14K |
| 4 |
Barclays
London,
United Kingdom
|
+$2.65K |
| 5 |
Morgan Stanley
New York
|
+$137 |
Top Sellers
IBO Hedge Fund Activity: Q3 2024 in Review
9 of the 6,979 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q3 2024, worth a combined $59.3K.
Buyers outnumbered sellers: 9 funds opened new IBO positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $31.6K.
- 9 institutional investors held Impact BioMedical (IBO) as of Q3 2024, up from 0 in Q2 2024.
- Funds reported $59.3K of Impact BioMedical stock for Q3 2024.
- 9 funds opened new Impact BioMedical positions in Q3 2024 and 0 closed out, a net change of +9 holders.
- The largest Impact BioMedical buyer in Q3 2024 was Jane Street, an estimated $31.6K added.
Based on aggregated 13F filings for Q3 2024.